Biomarkers in malignant pleural mesothelioma: current status and future directions

被引：18

作者：

Ahmadzada, Tamkin ^{[1
]}

Reid, Glen ^{[1
,2
]}

Kao, Steven ^{[2
,3
]}

机构：

[1] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[2] ADRI, Sydney, NSW, Australia

[3] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia

来源：

JOURNAL OF THORACIC DISEASE | 2018年 / 10卷

关键词：

DETECT ASBESTOS EXPOSURE; OPEN-LABEL; DIAGNOSIS; PROGNOSIS; TRIAL; OSTEOPONTIN; EXPRESSION; FIBULIN-3; HMGB1;

D O I：

10.21037/jtd.2018.04.31

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：S1003 / S1007

页数：5

共 25 条

[11] MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma [J].

Kirschner, Michaela B. ;

Cheng, Yuen Yee ;

Armstrong, Nicola J. ;

Lin, Ruby C. Y. ;

Kao, Steven C. ;

Linton, Anthony ;

Klebe, Sonja ;

McCaughan, Brian C. ;

van Zandwijk, Nico ;

Reid, Glen .

MOLECULAR ONCOLOGY, 2015, 9 (03) :715-726

[12] B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis [J].

Mansfield, Aaron Scott ;

Roden, Anja C. ;

Peikert, Tobias ;

Sheinin, Yuri M. ;

Harrington, Susan M. ;

Krco, Christopher J. ;

Dong, Haidong ;

Kwon, Eugene D. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (07) :1036-1040

[13]

Mauti L, 2017, ANN ONCOL, V28, P8

[14] HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients (Publication with Expression of Concern. See vol. 26, pg. 1529, 2020) [J].

Napolitano, Andrea ;

Antoine, Daniel J. ;

Pellegrini, Laura ;

Baumann, Francine ;

Pagano, Ian ;

Pastorino, Sandra ;

Goparaju, Chandra M. ;

Prokrym, Kirill ;

Canino, Claudia ;

Pass, Harvey I. ;

Carbone, Michele ;

Yang, Haining .

CLINICAL CANCER RESEARCH, 2016, 22 (12) :3087-3096

[15] The established and future biomarkers of malignant pleural mesothelioma [J].

Panou, V. ;

Vyberg, M. ;

Weinreich, U. M. ;

Meristoudis, C. ;

Falkmer, U. G. ;

Roe, O. D. .

CANCER TREATMENT REVIEWS, 2015, 41 (06) :486-495

[16] Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [J].

Pass, Harvey I. ;

Levin, Stephen M. ;

Harbut, Michael R. ;

Melamed, Jonathan ;

Chiriboga, Luis ;

Donington, Jessica ;

Huflejt, Margaret ;

Carbone, Michele ;

Chia, David ;

Goodglick, Lee ;

Goodman, Gary E. ;

Thornquist, Mark D. ;

Liu, Geoffrey ;

de Perrot, Marc ;

Tsao, Ming-Sound ;

Goparaju, Chandra .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (15) :1417-1427

[17] Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis [J].

Pei, Dongxu ;

Li, Yongwei ;

Liu, Xinwei ;

Yan, Sha ;

Guo, Xiaolan ;

Xu, Xiaona ;

Guo, Xiaoxia .

ONCOTARGET, 2017, 8 (08) :13030-13038

[18]

Reck M, 2016, ANN ONCOL, V27, pvi552

[19]

Rivalland G, 2017, P AM SOC CLIN ONCO S, V35, P8514

[20] Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma [J].

Sandri, Alberto ;

Guerrera, Francesco ;

Roffinella, Matteo ;

Olivetti, Stefania ;

Costardi, Lorena ;

Oliaro, Alberto ;

Filosso, Pier Luigi ;

Lausi, Paolo Olivo ;

Ruffini, Enrico .

JOURNAL OF THORACIC DISEASE, 2016, 8 (08) :2121-2127

← 1 2 3 →